1. Home
  2. CAL vs ORKA Comparison

CAL vs ORKA Comparison

Compare CAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caleres Inc.

CAL

Caleres Inc.

HOLD

Current Price

$12.21

Market Cap

450.1M

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$28.46

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAL
ORKA
Founded
1878
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
450.1M
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CAL
ORKA
Price
$12.21
$28.46
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$14.00
$48.20
AVG Volume (30 Days)
1.1M
684.0K
Earning Date
12-09-2025
11-12-2025
Dividend Yield
2.30%
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
$2,702,018,000.00
N/A
Revenue This Year
$2.22
N/A
Revenue Next Year
$3.67
N/A
P/E Ratio
$19.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.54
$5.49
52 Week High
$23.82
$32.64

Technical Indicators

Market Signals
Indicator
CAL
ORKA
Relative Strength Index (RSI) 43.34 43.99
Support Level $12.62 $28.15
Resistance Level $13.42 $32.64
Average True Range (ATR) 0.55 2.12
MACD -0.18 -0.31
Stochastic Oscillator 14.06 9.17

Price Performance

Historical Comparison
CAL
ORKA

About CAL Caleres Inc.

Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: